看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 17.8x - 19.6x | 18.7x |
| Selected Fwd Ps Multiple | 2.2x - 2.4x | 2.3x |
| Fair Value | kr1.63 - kr1.80 | kr1.71 |
| Upside | 3.0% - 13.8% | 8.4% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Bavarian Nordic A/S | - | CPSE:BAVA |
| Emergent BioSolutions Inc. | - | DB:ER4 |
| Zealand Pharma A/S | - | CPSE:ZEAL |
| Genmab A/S | - | CPSE:GMAB |
| FluoGuide A/S | - | OM:FLUO |
| BioPorto A/S | - | CPSE:BIOPOR |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| BAVA | ER4 | ZEAL | GMAB | FLUO | BIOPOR | |||
| CPSE:BAVA | DB:ER4 | CPSE:ZEAL | CPSE:GMAB | OM:FLUO | CPSE:BIOPOR | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 53.9% | -1.2% | 8.7% | 32.0% | NM- | 6.4% | ||
| 3Y CAGR | 44.4% | -16.2% | -16.7% | 36.8% | -65.8% | 14.3% | ||
| Latest Twelve Months | -19.1% | -0.5% | -81.7% | 30.7% | -9.0% | 17.1% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -0.3% | -13.1% | -758.9% | 36.8% | -3648.7% | -234.5% | ||
| Prior Fiscal Year | 20.9% | -72.5% | -205.3% | 26.4% | -9072.6% | -181.9% | ||
| Latest Fiscal Year | 17.3% | -18.3% | -1720.9% | 36.4% | -7521.8% | -188.3% | ||
| Latest Twelve Months | 17.3% | -18.3% | -1720.9% | 36.4% | -7521.8% | -188.3% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 6.3x | 16.0x | -19.3x | 9.1x | -10.6x | -8.9x | ||
| Price / LTM Sales | 2.1x | 0.3x | 525.9x | 4.0x | 952.7x | 19.6x | ||
| LTM P/E Ratio | 12.4x | -1.5x | -30.6x | 11.1x | -12.7x | -10.4x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 0.3x | 4.0x | 952.7x | |||||
| Historical LTM P/S Ratio | 19.6x | 26.5x | 48.3x | |||||
| Selected Price / Sales Multiple | 17.8x | 18.7x | 19.6x | |||||
| (x) LTM Sales | 36 | 36 | 36 | |||||
| (=) Equity Value | 644 | 678 | 712 | |||||
| (/) Shares Outstanding | 454.7 | 454.7 | 454.7 | |||||
| Implied Value Range | 1.42 | 1.49 | 1.57 | |||||
| FX Rate: DKK/DKK | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 1.42 | 1.49 | 1.57 | 1.58 | ||||
| Upside / (Downside) | -10.3% | -5.6% | -0.9% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | BAVA | ER4 | ZEAL | GMAB | FLUO | BIOPOR | |
| Value of Common Equity | 12,415 | 266 | 34,328 | 88,577 | 369 | 718 | |
| (/) Shares Outstanding | 77.8 | 54.3 | 70.7 | 62.3 | 13.6 | 454.7 | |
| Implied Stock Price | 159.55 | 4.89 | 485.70 | 1,421.50 | 27.07 | 1.58 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.13 | 1.00 | 1.00 | 0.68 | 1.00 | |
| Implied Stock Price (Trading Cur) | 159.55 | 4.33 | 485.70 | 1,421.50 | 39.60 | 1.58 | |
| Trading Currency | DKK | EUR | DKK | DKK | SEK | DKK | |
| FX Rate to Reporting Currency | 1.00 | 1.13 | 1.00 | 1.00 | 0.68 | 1.00 | |